NJA-730 / NapaJen Pharma  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
NJA-730 / NapaJen Pharma
ACTRN12618001428257: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NJA-730 in Healthy Volunteers

Completed
1
104
 
NapaJen Pharma Inc., NapaJen Pharma Inc.
Acute graft-versus-host disease (aGvHD)
 
 

Download Options